Jump Into an All-New Mickey & Friends Adventure with Disney Illusion Island on July 28
Embark on a brand-new adventure with Disney Mickey Mouse’s triumphant return to video games – and this time he’s bringing a few friends! Today, Disney, in collaboration with developer Dlala Studios, revealed that Disney Illusion Island , an upcoming local cooperative 2D platform adventure video game for up to four players, will debut exclusively for Nintendo Switch™ on July 28, 2023. Additionally, pre-orders for Disney Illusion Island are available for $39.99 in Nintendo eShop and at retail, beginning today.
“Fans are in for a treat with the upcoming launch of the whimsical cartoon-like experience offered by Disney Illusion Island,” said Luigi Priore, VP, Disney, Pixar and 20th Century Games. “We’re thrilled to work with developer Dlala Studios as they expand upon the Mickey & Friends world with a new and original storyline, engaging gameplay and delightful hand-drawn art style.”
Join Mickey Mouse, Minnie Mouse, Donald Duck and Goofy and set off on a perilous quest to explore the colorfully hand-crafted and yet mysterious island of Monoth in an escapade to recover three magical Tomes – powerful books used to protect the island. Featuring the voice actors of Mickey, Minnie, Donald, and Goofy and an original orchestral score, players can immerse themselves in a solo adventure or team up with up to three friends in local co-op to use special team skills such as Rope Drop, Leap Frog, and a heart gifting Hug to save the island. Discover rich biomes and never-before-seen environments, meet strange yet intriguing characters, and uncover hidden secrets galore!
But the journey will not be easy, and with intrigue afoot, not everything is what it seems on “Illusion Island.”
“Words cannot express how excited we are for players to embrace the Dlala-spin on this brand-new experience for Mickey Mouse, Minnie Mouse, Donald Duck and Goofy,” said AJ Grand-Scrutton, Lead Developer, Dlala Studios. “It has been an incredible honor working on this title and we hope that Nintendo Switch players and Disney fans worldwide love playing it as much as we've loved creating it.”
Disney Illusion Island will be available for $39.99 and will debut worldwide exclusively for Nintendo Switch on July 28, 2023.
For more information about Disney Illusion Island: https://games.disney.com/disney-illusion-island
To watch the latest trailer: https://www.youtube.com/watch?v=Ll9zSkf4Cfw
For Disney Illusion Island assets: https://drive.google.com/drive/folders/1sVurQkkRn_Tq94FDsbBipvWoP3-ssuhe?usp=sharing
For more updates on Disney Illusion Island, please follow us on social below:
About Dlala Studios
Dlala Studios are the creators of Battletoads (2020), and have previously worked on award-winning titles such as Sea of Thieves, The Escapists, and Lost Words: Beyond The Page. The Essex-based studio celebrated their 10th anniversary in 2022, and are currently developing Disney Illusion Island for the Nintendo Switch.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230209005020/en/
Contact information
MEDIA CONTACT
Disney Consumer Products, Games and Publishing
Dashaun Gasque
Communications Manager
DASHAUN.GASQUE@DISNEY.COM
Dylan Quintero
Senior Specialist, Communications
DYLAN.QUINTERO@DISNEY.COM
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 03:09:00 EEST | Press release
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio ha
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom